Nausea and Vomiting Induced by Motion Sickness Market

• The Nausea and Vomiting Induced by Motion Sickness market size was valued ~USD 796 million in 2022 and is anticipated to grow with a significant CAGR during the forecast period (2019-2032).
• Industrialization and expansion of modes of transport have led to an increase in nausea and vomiting induced by motion sickness in the US.
• Nausea and vomiting are well-recognized phenomena during travel, making it easier for individuals to recognize and identify the condition.
• There is no effective therapy to treat nausea and vomiting induced by motion sickness. The management involves a multidisciplinary approach, including nonpharmacological and pharmacological prevention and treatment options. Several OTC and generic drugs, including anticholinergics (scopolamine transdermal patches), antihistamines (cyclizine, dimenhydrinate, promethazine, meclizine, and others), and anti-emetics help prevent or reduce symptoms.
• Nonpharmacological therapies like behavioral and environmental modification and herbs may provide some relief. Herbs like ginger, lemon, fennel, peppermint, etc., and enhancing visual focus by aligning visual and vestibular cues in the direction of motion and other behavioral methods often prevent nausea and vomiting while traveling.
• The exact mechanism of underlying nausea and vomiting in motion sickness is complex and poorly understood. However, it is believed to be caused by a disconnect between what the eyes perceive and the inner ear’s vestibular system senses, leading to symptoms like nausea and vomiting.
• There is an opportunity for companies to invest in refining animal models that better mimic human experiences of nausea and vomiting to understand its pathophysiology and support clinical trials.
• The major concern in understanding the market for nausea and vomiting induced by motion sickness is a lack of epidemiology data and a paucity of evidence to validate interventions used in management. Further, the lack of established diagnostic and treatment guidelines for nausea and vomiting induced by motion sickness results in variability and therapy uncertainty.
• In 2022, the market size of nausea and vomiting induced by motion sickness was highest in the US among the 7MM, accounting for approximately USD 526.32 million. It is expected to increase by 2032.
• In EU4 and the UK, the current standard of care involves treatment with therapies like scopolamine, ondansetron, and others, generating a revenue of USD 174.69 million in 2022.
• The available treatment is limited by partial efficacy and unwanted side effects. Scopolamine is a nonselective anticholinergic agent and is the most effective and widely prescribed agent; however, it is associated with side effects like dry eyes/mouth, drowsiness, and tachycardia.
• Advances in research have led to the discovery of gel formulation and intranasal route of scopolamine that provides rapid onset of action.
• Emerging therapies, DPI-386 (scopolamine gel) and VLY-686 (tradipitant), can potentially create a positive shift in the market size of nausea and vomiting induced by motion sickness during the forecast period.
• Defender Pharmaceuticals’ DPI-386 (scopolamine gel) is a low-dose intranasal scopolamine gel that facilitates more rapid absorption and the onset of action of scopolamine. It is a naturally occurring muscarinic receptor antagonist and belladonna alkaloid that produces both peripheral antimuscarinic properties and central sedative, anti-emetic, and amnestic effects. It is projected to enter the US market by 2024.
• Vanda Pharmaceuticals and Eli Lilly’s VLY-686 (tradipitant) is a small NK-1 receptor antagonist that prevents vomiting. It is anticipated to enter the US market by 2025 with a slow uptake.

DelveInsight’s “Nausea and Vomiting Induced by Motion Sickness Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the nausea and vomiting induced by motion sickness historical and forecasted epidemiology as well as the Nausea and Vomiting Induced by Motion Sickness therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The nausea and vomiting induced by motion sickness market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted the 7MM nausea and vomiting induced by motion sickness market size from 2019 to 2032. The report also covers current nausea and vomiting induced by motion sickness treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Nausea and Vomiting Induced by Motion Sickness Treatment Market

Nausea and Vomiting Induced by Motion Sickness Overview

Motion sickness is a common physiological response that occurs when there is a sensory mismatch between the visual and vestibular systems. It usually manifests during the air, car, bus, train, or boat travel, leading to hallmark symptoms, nausea and vomiting.

The severity of symptoms can vary from mild discomfort to more severe reactions. Mild symptoms include malaise, headache, irritability, drowsiness, fatigue, etc. Moderate symptoms include nonvertiginous dizziness, apathy, depression, and disinterest in social activities, and severe symptoms include incapacitation, loss of postural stability, persistent retching, and social isolation of the individual.

Nausea is a subjective sensation that signals imminent emesis, while vomiting is the forceful removal of gastrointestinal contents. The sensation of nausea and the ability to vomit are key components of human defenses against motion sickness caused by traveling (car rides, bus rides, air travel, and boat trips) or unintentional ingestion of noxious material.

The exact mechanism of underlying nausea and vomiting in motion sickness is complex and poorly understood. However, it is believed to involve complex interactions between the inner ear, brainstem, and autonomic nervous system. The brain’s attempts to resolve sensory conflicts can activate vomiting centers, triggering the reflexive response.

Factors such as susceptibility due to genetics, previous experiences, and individual sensitivities increase the likelihood of developing motion sickness in individuals.

Nausea and Vomiting Induced by Motion Sickness Diagnosis

The clinical diagnosis of motion sickness includes a physical examination to rule out other possible causes of similar symptoms. The diagnostic methodology may include an evaluation of medical history, symptom description, activity history, motion challenge test, and physical examination. Additional workup through laboratory or radiographic tests is not required if a patient has a typical presentation or a prior history of motion sickness. Differential diagnoses of motion sickness include migraine, pregnancy, concussion, intoxication, hangover, basilar artery occlusion, cerebral vascular accident, vestibulopathy, hypoglycemia, depression, and anxiety.

Further details related to country-based variations are provided in the report…

Nausea and Vomiting Induced by Motion Sickness Treatment

A multidisciplinary approach involving both pharmacological and nonpharmacological agents treats or helps prevent nausea and vomiting induced by motion sickness. A visual focus, a distant point, appropriate ventilation, fresh air, preserving body posture, and controlling attentive breathing are behavioral strategies that can assist in minimizing the sensory conflict between the eyes and the inner ear. Over time, some individuals can become less sensitive to motion sickness through repeated exposure to the triggering motion. For example, sailors may experience reduced symptoms after spending more time at sea.

Motion sickness medications are only sporadically useful and can have negative side effects. The drugs should be tested securely before being used at work or traveling. There are three subcategories of medications: Sympathomimetic, anticholinergic, and antihistamine.

Scopolamine patch and promethazine are anticholinergic drugs that prevent motion sickness by obstructing signals from the vestibular system to the brain’s vomiting center. Scopolamine transdermal patches deliver long-lasting comfort behind the ear. Antihistamines such as promethazine, dimenhydrinate, cyclizine, meclizine, and cinnarizine are also used. They work by obstructing histamine receptors in the brain, lowering vestibular sensitivity, and decreasing the brain’s reaction to motion-related signals, all of which help prevent motion sickness. Further, H1-antihistamines with the lowest possible potential for sedation are the main treatment for vertigo, nausea, and vomiting due to motion sickness.

Nausea and Vomiting Induced by Motion Sickness Epidemiology

As the market is derived using a patient-based model, the nausea and vomiting induced by motion sickness epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total cases of motion sickness, total cases of motion sickness by mode of transport, total cases of nausea and vomiting in motion sickness by mode of transport in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

• In 2022, there were approximately 217,237,382 total cases of motion sickness in the 7MM. These cases are expected to increase by 2032.
• In 2022, among the 7MM, the US accounted for the highest cases of motion sickness, contributing nearly 52%, while Japan accounted for the least, with around 14% of the total cases of motion sickness.
• Among EU4 and the UK, France accounted for the highest cases of motion sickness with around 17,076,287 cases, followed by the UK with 16,947,850 cases, while Spain accounted for the least cases, 11,790,855, in 2022.
• In the US, motion sickness due to travel by car and bus was the highest, with 33,734,195 cases in each mode. This was followed by motion sickness due to travel by train with 22,489,464 cases, airplanes with 16,867,098 cases, and others in 2022. These cases are projected to increase by 2032.
• In EU4 and the UK, based on the modes of transport, around 30% of motion sickness cases occur when traveling by car and bus in each of the two modes, followed by nearly 20% of cases by train, 15% by airplane, and 5% by boat/ship, in 2022.
• In 2022, in Germany, around 3,794,248 individuals had nausea, and 682,965 had vomiting traveled by car and bus, while 346,624 and 190,894 individuals had nausea and vomiting, respectively, while traveling by boat/ship.
• In 2022, Japan accounted for the second-highest cases of motion sickness among the 7MM, with nearly 31,053,692 cases, of which 15,247,363 individuals had nausea and vomiting. These cases are expected to change during the forecast period.

Stay Informed on Nausea and Vomiting Induced by Motion Sickness Epidemiology! Access comprehensive data on demographics and disease burden for effective healthcare planning.

Nausea and Vomiting Induced by Motion Sickness Drug Chapters

The drug chapter segment of nausea and vomiting induced by motion sickness report encloses a detailed analysis of nausea and vomiting induced by motion sickness, currently used drugs, and late-stage (Phase III) pipeline drugs. It also helps understand the nausea and vomiting induced by motion sickness clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Nausea and Vomiting Induced by Motion Sickness Drugs

DPI-386 (scopolamine gel): Defender Pharmaceuticals

DPI-386 is a low-dose intranasal scopolamine gel investigated by Defender Pharmaceutical, also called Repurposed Therapeutics. Scopolamine is a naturally occurring muscarinic receptor antagonist and belladonna alkaloid. It competitively inhibits G-protein coupled post-ganglionic muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, anti-emetic, and amnestic effects. TRANSDERM SCOP (scopolamine transdermal patch [TDS]) is approved for postoperative nausea and vomiting (PONV) associated with recovery from anesthesia, opiate analgesia, and surgery and nausea and vomiting associated with motion sickness.

DPI-386 is undergoing Phase II trials to mitigate G-transition-induced motion sickness and has filed for US FDA approval to prevent nausea and vomiting induced by motion, with anticipated acceptance by September 2023. Further, the company is also investigating the drug for treating PONV and virtual reality.

VLY-686 (tradipitant): Vanda Pharmaceuticals/Eli Lilly

VLY-686 (tradipitant) is a small molecule neurokinin-1 (NK-1) receptor antagonist. The presumed mechanism of tradipitant to treat the core symptoms of motion sickness is acting at the level of the NK1 receptors in the brainstem to prevent vomiting and at the gut, influencing nauseogenic pathways and gastric motility.

The drug has completed two Phase II trials and is undergoing a Phase III trial in participants affected by motion sickness during travel. Further, the drug is also being investigated for treating gastroparesis, atopic dermatitis, and COVID-19 pneumonia.

Note: Detailed emerging therapies assessment will be provided in the final report...

Drug Class Insights

Current treatment approaches for nausea and vomiting induced by motion sickness are limited, with marginal efficacy and undesirable side effects. Different classes of therapies like anticholinesterase (scopolamine), antihistamines, anti-emetics, and others prevent or treat symptoms. Scopolamine is a nonselective anticholinergic agent and is presently the most effective and prescribed agent. Besides, many first-generation antihistamines effectively prevent and treat motion sickness, including cinnarizine, promethazine, dimenhydrinate, diphenhydramine, and others. Further, anti-emetics like ondansetron, a 5-HT3 receptor antagonist, are sometimes used to inhibit gastric tachyarrhythmia to treat vomiting.

Antihistamines: First-generation antihistamines are used to treat motion sickness. A histaminergic neuron system is involved in the symptomatic mechanism of motion sickness via H1-receptors; this group of medicines can reduce the severity of the symptoms and signs of motion sickness by blocking the emetic linkage. They are generally recommended for patients who can tolerate their sedative effects. Cyclizine (Marezine), dimenhydrinate, promethazine, and meclizine (Antivert) demonstrate effectiveness.

Anticholinergics: Scopolamine, an anticholinergic, is a first-line option for preventing motion sickness in persons who maintain wakefulness during travel. Transdermal patches are most effective; one patch is applied to the mastoid at least 4 h before travel, then every 72 h as needed. The dose may be doubled if the recommended dose does not relieve symptoms. Furthermore, oral scopolamine treatment is moderately effective.

Benzodiazepines: Benzodiazepines are occasionally administered for severe symptoms of motion sickness. Vertigo has been treated empirically with diazepam, and there is evidence from trials on animals that this medication may also depress the vestibular system. Although not as well as other methods, (benzodiazepines like diazepam) are not recommended to prevent motion sickness due to their sedative qualities.

Monoamine antagonists/agonists: Dopamine D2 and D3 receptors are known to play a role in nausea and emesis. They can alter the amount of cAMP within neurons of the vomiting center via inhibiting adenylate cyclase. Competitive D2 receptor antagonist metoclopramide, administered through IV or intramuscular injection but not oral route, alleviated overall symptoms and restored gastric emptying after the initiation of motion sickness. In addition, orally administered domperidone, a peripherally restricted D2 receptor antagonist and a1-adrenoceptor antagonist, failed to prevent spatial disorientation-induced gastric dysrhythmia and motion sickness symptoms in humans.

Stimulants and sedatives: Sympathomimetic d-amphetamine is highly effective against space motion sickness rather than seasickness. The d-amphetamine and ephedrine counteract the sedative side effects of scopolamine and antihistamines but at the risk of drug addiction and counterbalancing the vestibular suppression effect. Furthermore, modafinil, a potential substitute for amphetamine, significantly enhanced scopolamine’s efficacy when combined. Dextroamphetamine synergizes with anticholinergics and antihistamines by stimulating the dopaminergic and noradrenergic pathways. Studies demonstrate dextroamphetamine and scopolamine as the most effective anti-motion sickness combination as they act through different pathways, and their respective side effects cancel each other out. However, the drug dependence risk must be considered.

Neuroleptics: In the treatment of motion sickness, phenothiazine is primarily used, but this treatment has a stronger sedative effect compared to antihistamines. The effect is based on an anti-dopamine influence in the chemoreceptive emetic trigger zone. The intranasal application of promethazine offers great promise as an effective, noninvasive alternative for treating space motion sickness. Due to its rapid absorption and bioavailability equivalent, the intramuscular dose is recommended.

Nausea and Vomiting Induced by Motion Sickness Market Outlook

Nausea and vomiting are common occurrences after a triggering motion or event, usually known as motion sickness. Motion sickness is a condition that occurs when there is a disconnect between the sensory inputs the brain receives. This disconnect can happen when conflicting signals are sent by the inner ears, eyes, and other sensory receptors to the brain regarding the body’s motion and orientation. It can occur in various situations when traveling by car, boat, airplane, amusement park rides, etc. The conflicting sensory inputs can lead to symptoms like nausea, vomiting, dizziness, sweating, and general discomfort. It is usually diagnosed through history and physical examination. Treatment involves a combination of preventive measures, lifestyle changes, and, in some cases, medications.

Largely, the market of nausea and vomiting induced by motion sickness is occupied by over-the-counter (OTC) medications and generic forms of antihistamines, anticholinergics, benzodiazepines, dopamine receptor antagonists, and sympathomimetics, and others are also used. Over the past four decades, since the approval of the scopolamine transdermal patch, no other treatment has been approved by the US FDA for treating nausea and vomiting induced by motion sickness, and no consensus treatment guidelines are available.

Besides, nonpharmacological treatments relieve nausea and vomiting in motion sickness, for instance, reducing sensory conflict. Supplements and herbs are commonly used for nausea and may relieve motion sickness; however, no credible studies show that herbs used for motion sickness treatment are safe or work. Ginger, peppermint, black horehound, and others are being used. Further, acupressure bands are commercially available that may help reduce symptoms of motion sickness or delay its onset. Homeopathic remedies like Borax, Cocclus, Nux Vomica, Petroleum, Sepia, and others are sometimes used for nausea.

Further, awareness and avoidance of situations that trigger symptoms are the primary defenses against motion sickness. Looking outside the window, rapid and shallow breathing, sitting in the front of a car or bus, avoiding smoking, and eating small amounts of food frequently are common preventive measures for nausea and vomiting during travel.

Available medications for treating motion sickness are partially effective and may have unwanted side effects. They are most effective when used prophylactically or at the early onset of symptoms. Scopolamine is the most effective agent presently, acting as a nonselective antimuscarinic by inhibiting input to the vestibular nuclei. It has less sedation than antihistamines and is available by prescription in the US as a transdermal patch. In 1979, the US FDA approved TRANSDERM SCOP (scopolamine) transdermal system patch, an anticholinergic agent indicated in adults to prevent nausea and vomiting associated with motion sickness. It is applied in the postauricular area or back of the ear for 4 h before an anti-emetic effect is required and can be used for up to 3 days. In case of a longer use than 3 days, removing the current patch and placing a new one behind the other ear is recommended. The drug has common side effects, including dry eyes/mouth, photosensitivity, blurred vision, dizziness, headache, and sedation. Further, the drug is not recommended for children under 12 years old and is used cautiously in the elderly. Some rare side effects include acute angle glaucoma, confusion, contact dermatitis, and urinary retention.

The role of antihistamines in motion sickness was discovered in 1949; since then, it has been used frequently to treat motion sickness symptoms. They are available as over-the-counter and by prescription. Some common antihistamines include dimenhydrinate, chlorpheniramine, diphenhydramine, meclizine, and others. Specifically, antihistamines with central cholinergic blocking properties have proven efficacy in treating or preventing motion sickness. Thus, the anti-motion sickness effects of antihistamines are due not to the blockade of H1 receptors but to their effects as central-acting anticholinergics. Unfortunately, H1 antagonists are highly sedating. Studies have determined the less sedating second-generation antihistamines to be ineffective in treating motion sickness, likely due to mediation via peripheral versus central receptors. The main dosage forms of antihistamines include oral (all), intramuscular injection (promethazine and cyclizine), suppository (promethazine), chewing gum (dimenhydrinate), and sublingual form (dimenhydrinate).

First-generation antihistamines are both peripheral and central-acting. Consequently, the antihistamines used to treat motion sickness are generally first-generation agents. Diphenhydramine, a commonly used antihistamine, possesses anticholinergic properties and is available in oral (OTC) and injectable preparations. Sedation is common; other side effects include dry mouth/eyes, blurred vision, and photosensitivity. Further, dimenhydrinate is used to prevent motion sickness, discomfort, and vomiting while traveling, taken every 4–8 h. For children aged 2–12 years, DRAMAMINE (dimenhydrinate), 1–1.5 mg/kg per dose, or BENADRYL (diphenhydramine), 0.5–1 mg/kg per dose up to 25 mg, can be given 1 h before travel and every 6 h during the trip.

Promethazine, a prescription medication available in oral, rectal, and intramuscular preparations, has the strongest antihistaminic and anticholinergic properties and is the most effective antihistamine in the class. It has also been studied in space motion sickness, where intramuscular injections are commonly used; however, its side effects may impair operational performance. Combination therapy with caffeine has proven effective in counteracting some side effects of promethazine.

Other first-generation antihistamines like cyclizine, meclizine, and cinnarizine are also used. However, cinnarizine is unavailable in the US due to its calcium channel-blocking properties, but it is still widely used in European countries. Second-generation antihistamines, such as cetirizine and fexofenadine, have been considered but have not proven efficacious, likely due to their insufficient central-acting properties.

In 2010, Eisai launched TRAVELMIN 1 as a rapidly disintegrating motion sickness remedy for adults whose active ingredients, comprising an antihistaminic (meclizine hydrochloride) and an anticholinergic (scopolamine hydrobromide hydrate), act to prevent and alleviate dizziness, nausea, headaches, and other symptoms associated with motion sickness. Eisai has launched several other OTC motion sickness remedies.

Other pharmacological agents like sympathomimetics, anti-emetics, benzodiazepines, anticonvulsants, and tricyclic antidepressants have been investigated to treat motion sickness.

Prochlorperazine, a prescription-only medicine, works by changing the actions of the chemicals that control the tendency to be sick (vomit) in the brain. One form of prochlorperazine is BUCCASTEM, which is absorbed through the gums and does not need to be swallowed. It tastes rather bitter, but it can be effective for sickness when there is already a feeling of sickness, as it does not have to be absorbed by the stomach.

Amphetamine and psychostimulants have been demonstrated to be effective in preventing motion sickness. In particular, the combination of methamphetamine with scopolamine or with promethazine is the most effective for prophylaxis. It is suggested that general arousal activated by amphetamine prevents motion sickness and is especially effective in relieving drowsiness.

The current treatment market for nausea and vomiting induced by motion sickness lacks licensed pharmacological therapy and treatment guidelines, leading to the use of generic or off-label drugs, where the efficacy of medicines is limited and has unwanted side effects. Despite being a widespread occurrence, research and development are restricted, and the current emerging pipeline remains limited, with only a few trials. Nevertheless, a few companies are working to bring novel therapies that can fulfill this unmet need of motion sickness, making travel more convenient to the common population and military personnel across land, sea, air, and space environments.

Intranasal scopolamine has been of particular interest in recent studies conducted by NASA to address the significant discomfort of space motion sickness in astronauts. The nasal gel formulation of scopolamine, DPI-386, has been found to have a more rapid absorption and onset of action than its transdermal or oral counterparts, with a more predictable efficacy and favorable side effect profile. Defender Pharmaceuticals are developing it in collaboration with the US Navy and NASA. Further, Vanda Pharmaceuticals and Eli Lilly are investigating VLY-686 (tradipitant), an NK-1 receptor antagonist with the potential to improve the symptoms of motion sickness. Hence, if approved, they will significantly change the market scenario during the forecast period (2023–2032).

The current market has been covered by various drugs used off-label across the 7MM. Different therapies like anticholinesterase (scopolamine), antihistamines, anti-emetics, and others were the major drug classes considered for the current treatment in the forecast model.

Key players Defender Pharmaceuticals (DPI-386 [scopolamine gel]), Vanda Pharmaceuticals, and Eli Lilly’s VLY-686 (tradipitant) are evaluating their lead candidates in the late stages of clinical development. They aim to investigate their products for treating nausea and vomiting induced by motion sickness.

• The total market size of nausea and vomiting induced by motion sickness in the 7MM was approximately USD 796.06 million in 2022 and is projected to increase during the forecast period (2023–2032).
• According to DelveInsight’s estimates, among the 7MM, the US had the largest market share for nausea and vomiting induced by motion sickness, with a revenue of nearly USD 526.32 million in 2022, and will increase during the forecast period due to increasing population and the launch of the emerging therapies.
• Among EU4 and the UK countries, France accounted for the maximum market size of nausea and vomiting induced by motion sickness in 2022, while Spain occupied the bottom of the ladder.
• Japan captured the second largest market share of nausea and vomiting induced by motion sickness among the 7MM, with a revenue of approximately USD 95.06 million in 2022, expected to change during the forecast period.
• In Japan, the standard of care accounted for around USD 95.06 million in 2022, which is expected to decrease with the entry of new therapies in the market by 2032.
• Though the pipeline is limited, two therapies, DPI-386 (scopolamine gel) and VLY-686 (tradipitant), will enter the market during the forecast period.
• Vanda Pharmaceuticals and Eli Lilly’s VLY-686 (tradipitant) is a small NK-1 receptor antagonist that prevents vomiting. It is anticipated to enter the US market by 2025, generating a revenue of USD 0.77 million in its entry year.
• Defender Pharmaceuticals’ DPI-386 (scopolamine gel) will attain its peak share by the seventh year and will capture nearly 35% of total nausea and vomiting induced by the motion sickness market in EU4 and the UK by 2032.

Nausea and Vomiting Induced by Motion Sickness Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2019–2032. For example, DPI-386 (scopolamine gel) is a low-dose intranasal scopolamine gel expected to enter the US market by 2024 with a slow-medium uptake due to competition from the available therapies.

Further detailed analysis of emerging therapies drug uptake in the report…

Nausea and Vomiting Induced by Motion Sickness Pipeline Development Activities

The report provides insights into Nausea and Vomiting Induced by Motion Sickness clinical trials within Phase III. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for nausea and vomiting induced by motion sickness.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on nausea and vomiting induced by motion sickness evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the University of Vermont, Southwestern Oklahoma State University, University of California, Barcelona San Joan de Deu Center, University of Manchester, and Juntendo University Shizuoka Hospital were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns for nausea and vomiting induced by motion sickness market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician’s View

According to our primary research analysis, though there is a lack of treatment guidelines and approved therapies, the commonly prescribed pharmacological treatments are anticholinergics, antihistamines, and anti-emetics, while other treatments like dopamine receptor antagonists, sympathomimetics, and benzodiazepines are rarely used. Further, the scopolamine transdermal patch, the most effective and widely prescribed agent, acts as a nonselective antimuscarinic by inhibiting input to the vestibular nuclei.

Apart from medicinal therapies, the market is affected by other preventive nonpharmacological measures, including sensory input modification, homeopathic remedies, and ginger. Although ginger is most commonly used as a culinary spice, it is believed to have many medicinal properties, including treating motion sickness. Further, some behavioral measures prevent motion sickness by modifying the sensory pattern responsible for the neural mismatch signal.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. The effectiveness of these therapies was analyzed by giving them scores based on a reduction in the incidence of vomiting and motion sickness.

The therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement is the price negotiation between the manufacturer and payer that allows the manufacturer access to that market. It is provided to reduce the high costs and make essential drugs affordable. Market access refers to all patients’ ability to access a given product quickly, conveniently, and affordably.

Several drugs are available as OTC or off-label for treating nausea and vomiting induced by motion sickness. However, there is a lack of approved and effective therapies; TRANDERM SCOP is the only approved drug for nausea and vomiting associated with motion sickness. Hence, there is limited accessibility to treatment, and management relies on a multidisciplinary approach, including OTC drug, nonpharmacological, and pharmacological approaches.

Capital District Physicians’ Health Plan (CDPHP) Medicare Advantage Drug Plans generally cover scopolamine as long as the drug is medically necessary, the prescription is filled at a CDPHP Medicare Advantage Drug Plans network pharmacy, and other plan rules are followed. Scopolamine 1 mg/3 days patch 72 h falls under drug Tier 3 preferred brand in which Network Retail Cost Sharing (30-day supply) provides USD 40–47 copayment, depending upon the plan.

Scope of the Nausea and Vomiting Induced by Motion Sickness Market Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of nausea and vomiting induced by motion sickness, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the nausea and vomiting induced by the motion sickness market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis, expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM nausea and vomiting induced by the motion sickness market.

Nausea and Vomiting Induced by Motion Sickness Report Insights

• Nausea and Vomiting Induced by Motion Sickness Patient Population
• Nausea and Vomiting Induced by Motion Sickness Therapeutic Approaches
• Nausea and Vomiting Induced by Motion Sickness Pipeline Analysis
• Nausea and Vomiting Induced by Motion Sickness Market Size and Trends
• Existing and Future Market Opportunity

Nausea and Vomiting Induced by Motion Sickness Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Nausea and Vomiting Induced by Motion Sickness Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Nausea and Vomiting Induced by Motion Sickness Report Assessment

• Current Nausea and Vomiting Induced by Motion Sickness Treatment Practices
• Nausea and Vomiting Induced by Motion Sickness Unmet Needs
• Nausea and Vomiting Induced by Motion Sickness Pipeline Product Profiles
• Nausea and Vomiting Induced by Motion Sickness Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Nausea and Vomiting Induced by Motion Sickness Market Drivers
• Nausea and Vomiting Induced by Motion Sickness Market Barriers

Key Questions Answered In The Nausea and Vomiting Induced by Motion Sickness Market Report

Nausea and Vomiting Induced by Motion Sickness Market Insights

• What was the total market size of nausea and vomiting induced by motion sickness, the market size by therapies for nausea and vomiting induced by motion sickness, market share (%) distribution in 2019, and what would it look like by 2032? What are the contributing factors for this growth?
• How will DPI-386 (scopolamine gel) and VLY-686 (tradipitant) affect nausea and vomiting induced by the motion sickness treatment paradigm?
• How will current therapies compete with other emerging therapies?
• Which drug is going to be the largest contributor by 2032?
• What are the pricing variations among different geographies for off-label therapies?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Nausea and Vomiting Induced by Motion Sickness Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of nausea and vomiting induced by motion sickness? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to nausea and vomiting induced by motion sickness?
• What is the historical and forecasted patient pool of nausea and vomiting induced by motion sickness in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Out of the countries mentioned above, which country would have the highest cases of nausea and vomiting induced by motion sickness during the forecast period (2023–2032)?
• What factors contribute to the growth of nausea and vomiting induced by motion sickness cases?

Current Nausea and Vomiting Induced by Motion Sickness Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options to treat nausea and vomiting induced by motion sickness?
• How many companies are developing therapies for treating nausea and vomiting induced by motion sickness?
• How many emerging therapies are in the late stage of development for treating nausea and vomiting induced by motion sickness?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What is the cost burden of current treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the accessibility issues of approved therapy in the US?
• What is the 7MM historical and forecasted market of nausea and vomiting induced by motion sickness?

Reasons to Buy Nausea and Vomiting Induced by Motion Sickness Market Forecast Report

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the nausea and vomiting induced by the motion sickness market.
• Insights on patient burden, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.